Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Opens 17% Up

If you are planning to invest money in stock market then you must subscribe to FREE Alerts by visiting: http://www.pennystockpickreport.com/

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) soared 17% to $1.64 after it announced that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). Top-line results showed that treatment with one gram of LX1031 four times daily produced a statistically significant improvement in global assessment of relief of IBS pain and discomfort over the four-week dosing period as compared to placebo (p=0.0465). Improvements in global assessment parameters also corresponded with statistically significant improvements in stool consistency. Notably, increased clinical response correlated with a greater reduction in serotonin synthesis as reflected by measures of urinary 5-HIAA, a breakdown product of serotonin.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets.

ABOUT PennyStockPickReport.com

 Penny Stock Pick Report is an independent electronic publication that provides information on selected publicly traded companies. Penny Stock Pick Report is not a registered investment advisor or broker-dealer. Penny Stock Pick Report affiliates, directors, officers, and employees may purchase and sell additional shares in any company which are mentioned above and may profit in the event those shares rise in value. Please do your research before you plan to invest in any of the stocks mentioned above.